Clinical Report: Novel diagnostic and treatment strategies for poorly cohesive gastric cancer
Overview
Poorly cohesive gastric cancer (PCGC) is a distinct subtype characterized by diffuse growth and poor prognosis. This review highlights emerging targeted therapies and advanced diagnostic technologies.
Background
PCGC presents significant clinical challenges due to its aggressive nature and unfavorable outcomes compared to other gastric cancer subtypes. The lack of established treatments specific to PCGC is noted. Recent advancements in molecular profiling and targeted therapies are discussed.
Data Highlights
No specific numerical data or trial results were provided in the source material.
Key Findings
PCGC is defined by discohesive malignant cells and significant intratumoral heterogeneity.
Current treatment primarily involves systemic chemotherapy, which has limited efficacy in PCGC.
Emerging molecular targets include HER2, PD-L1, CLDN18.2, FGFR2b, and TROP2.
Novel therapies such as antibody-drug conjugates and bispecific antibodies are being explored.
Advancements in digital pathology and multi-omics may enhance diagnostic accuracy.
Clinical Implications
Pathologists play a crucial role in identifying actionable biomarkers that can guide targeted therapies.
Conclusion
Further validation of innovative therapeutic approaches and advanced diagnostic technologies is required.
